← Eichor
Study identifier: NCT04797286 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Sildenafil for Early Pulmonary Vascular Disease in Scleroderma

Condition: Scleroderma · Mildly Elevated Pulmonary Pressures  ·  Sponsor: Johns Hopkins University

PhasePhase 2
Planned participants30
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a Phase II randomized, double-blind, placebo-controlled trial of sildenafil in men and women with Scleroderma with mildly elevated pulmonary pressures (SSc-MEP) to determine whether sildenafil may be an effective treatment for SSc-MEP.

This description comes directly from the study's public registry record.

Talk to the study team

Stephen Mathai, MD  ·  4106146311  ·  smathai4@jhmi.edu

Renee Ofori  ·  410-614-6311  ·  rofori2@jhu.edu

Always discuss trial participation with your own doctor first.

Locations (2)

Louisiana State UniversityNew Orleans, Louisiana, United StatesNot Yet Recruiting
Johns HopkinsBaltimore, Maryland, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04797286